Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Valero Energy Corporation (VLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Valero Energy Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Valero Energy Corporation trades at $279.51 (market cap $79.05B). The key difference: Valero Energy Corporation is far larger — about 17.6× ACADIA Pharmaceuticals Inc.'s market cap, and Valero Energy Corporation pays a 1.8% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | VLO | |
|---|---|---|
Market Cap | $4.49B | $79.05B |
Sector | Health | Energy |
52-Week High | $28.06 | $270.32 |
52-Week Low | $20.06 | $131.77 |
Enterprise Value | $3.69B | $84.81B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Valero Energy (VLO) trades at $266.22, down 0.58% on the day, with strong technical momentum showing bullish moving averages and key resistance at $270. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 expected at $10.08 EPS. Fundamentals show solid profitability with 17.72% ROE and attractive valuation metrics including P/E of 19.75 and P/S of 0.66. Recent news highlights VLO's refining strength and renewable fuels growth potential.
VLO presents a compelling investment case with strong analyst support (58% buy ratings) and a consensus price target of $258.25. The company's Gulf Coast refining advantage and clean-fuel initiatives support long-term growth, though investors face risks from energy market volatility and declining revenue trends from $176.4B in 2022 to $122.7B in 2025. The current price near resistance levels suggests potential for breakout or consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
